Potential Mechanisms Underlying the Therapeutic Roles of Gancao
fuzi Decoction in Cold-dampness Obstruction Syndrome-type Knee
Osteoarthritis

Jinlong      Zhao; Guihong      Liang; Hetao      Huang; Weiyi      Yang; Jianke      Pan; Minghui      Luo; Lingfeng      Zeng; Jun      Liu

doi:10.2174/1573409919666230605115940

Abstract

Background: The key active components and potential molecular mechanism of Gancao Fuzi decoction (GFD) in the treatment of cold-dampness obstruction-type knee osteoarthritis (KOA) remain unclear.

Objectives: To explore the mechanism of GFD in the treatment of cold-dampness obstruction syndrome-type KOA by network pharmacology.

Methods: The potential active components and targets of the four herbs in GFD (Fuzi, Guizhi, Baizhu, and Gancao) were screened using the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database. The targets of KOA were obtained with the Comparative Toxicogenomics Database (CTD), the GeneCards database, and the DisGeNET database, and the common targets of the drugs and disease were ultimately obtained. Cytoscape (v.3.7.1) was used to draw the active component-target network, and the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) (v.11.0) database was used to construct the protein interaction network. The Database for Annotation, Visualization, and Integrated Discovery (DAVID) was used for the Gene Ontology (GO) function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses of the intersecting targets.

Results: A total of 102 potential active components and 208 targets of GFD in the treatment of cold-dampness obstruction syndrome-type KOA were screened. GFD treatment was found to be closely related to many inflammatory signalling pathways in the treatment of KOA.

Conclusion: The effect of GFD on cold-dampness obstruction syndrome-type KOA is mediated by multicomponent, multitarget, and multichannel mechanisms, which provides the basis for further experimental study of its pharmacodynamic material basis and mechanism.

« Previous Next »

Graphical Abstract

[1]
Bichsel, D.; Liechti, F.D.; Schlapbach, J.M.; Wertli, M.M. Cross-sectional analysis of recommendations for the treatment of hip and knee osteoarthritis in clinical guidelines. Arch. Phys. Med. Rehabil.,  2022, 103(3), 559-569.e5.
 [http://dx.doi.org/10.1016/j.apmr.2021.07.801] [PMID: 34411512]

[2]
Carlesso, L.C.; Feldman, D.E.; Vendittoli, P.A.; LaVoie, F.; Choinière, M.; Bolduc, M.È.; Fernandes, J.; Newman, N.; Sabouret, P. Use of IMMPACT recommendations to explore pain phenotypes in people with knee osteoarthritis. Pain Med.,  2022, 23(10), 1708-1716.
 [http://dx.doi.org/10.1093/pm/pnac044] [PMID: 35266543]

[3]
Filardo, G.; Kon, E.; Longo, U.G.; Madry, H.; Marchettini, P.; Marmotti, A.; Van Assche, D.; Zanon, G.; Peretti, G.M. Non-surgical treatments for the management of early osteoarthritis. Knee Surg. Sports Traumatol. Arthrosc.,  2016, 24(6), 1775-1785.
 [http://dx.doi.org/10.1007/s00167-016-4089-y] [PMID: 27043347]

[4]
Litwic, A.; Edwards, M.H.; Dennison, E.M.; Cooper, C. Epidemiology and burden of osteoarthritis. Br. Med. Bull.,  2013, 105(1), 185-199.
 [http://dx.doi.org/10.1093/bmb/lds038] [PMID: 23337796]

[5]
Murphy, L.; Helmick, C.G. The impact of osteoarthritis in the United States: A population-health perspective: A population-based review of the fourth most common cause of hospitalization in U.S. adults. Orthop. Nurs.,  2012, 31(2), 85-91.
 [http://dx.doi.org/10.1097/NOR.0b013e31824fcd42] [PMID: 22446800]

[6]
Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation-United States, 2010-2012. MMWR Morb. Mortal. Wkly. Rep.,  2013, 62(44), 869-873.
 [PMID: 24196662]

[7]
Razumov, A.N. Purigа, A.O.; Yurova, O.V. The long-term results of the application of the combined rehabilitative treatment in the patients presenting with knee osteoarthrosis. Vopr. Kurortol. Fizioter. Lech. Fiz. Kult.,  2015, 92(6), 42-44.
 [http://dx.doi.org/10.17116/kurort2015642-44] [PMID: 26841528]

[8]
Farpour, H.R.; Fereydooni, F. Comparative effectiveness of intra-articular prolotherapy versus peri-articular prolotherapy on pain reduction and improving function in patients with knee osteoarthritis: A randomized clinical trial. Electron. Physician,  2017, 9(11), 5663-5669.
 [http://dx.doi.org/10.19082/5663] [PMID: 29403602]

[9]
Deng, W. Clinical research on Gancao fuzi decoction in treating osteoarthritis of knee joint. Zhong Yao Cai,  2008, 31(7), 1107-1110.
 [http://dx.doi.org/10.13863/j.issn1001-4454.2008.07.007] [PMID: 18973027]

[10]
Nazari, G. Knee osteoarthritis. J. Physiother.,  2017, 63(3), 188.
 [http://dx.doi.org/10.1016/j.jphys.2017.04.004] [PMID: 28633882]

[11]
Farber, J.M. The knee, osteoarthritis and biomarkers. Osteoarthritis Cartilage,  2018, 26(7), 845-846.
 [http://dx.doi.org/10.1016/j.joca.2018.01.023] [PMID: 29426011]

[12]
Li, S.; Zhang, B. Traditional Chinese medicine network pharmacology: Theory, methodology and application. Chin. J. Nat. Med.,  2013, 11(2), 110-120.
 [http://dx.doi.org/10.1016/S1875-5364(13)60037-0] [PMID: 23787177]

[13]
Hong, M.; Zhang, Y.; Li, S.; Tan, H.; Wang, N.; Mu, S.; Hao, X.; Feng, Y. A network pharmacology-based study on the hepatoprotective effect of Fructus Schisandrae. Molecules,  2017, 22(10), 1617.
 [http://dx.doi.org/10.3390/molecules22101617] [PMID: 28956809]

[14]
Tao, W.; Xu, X.; Wang, X.; Li, B.; Wang, Y.; Li, Y.; Yang, L. Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal Radix Curcumae formula for application to cardiovascular disease. J. Ethnopharmacol.,  2013, 145(1), 1-10.
 [http://dx.doi.org/10.1016/j.jep.2012.09.051] [PMID: 23142198]

[15]
Ru, J.; Li, P.; Wang, J.; Zhou, W.; Li, B.; Huang, C.; Li, P.; Guo, Z.; Tao, W.; Yang, Y.; Xu, X.; Li, Y.; Wang, Y.; Yang, L. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J. Cheminform.,  2014, 6(1), 13.
 [http://dx.doi.org/10.1186/1758-2946-6-13] [PMID: 24735618]

[16]
Dimmer, E.C.; Huntley, R.P.; Alam-Faruque, Y.; Sawford, T.; O’Donovan, C.; Martin, M.J.; Bely, B.; Browne, P.; Mun Chan, W.; Eberhardt, R.; Gardner, M.; Laiho, K.; Legge, D.; Magrane, M.; Pichler, K.; Poggioli, D.; Sehra, H.; Auchincloss, A.; Axelsen, K.; Blatter, M.C.; Boutet, E.; Braconi-Quintaje, S.; Breuza, L.; Bridge, A.; Coudert, E.; Estreicher, A.; Famiglietti, L.; Ferro-Rojas, S.; Feuermann, M.; Gos, A.; Gruaz-Gumowski, N.; Hinz, U.; Hulo, C.; James, J.; Jimenez, S.; Jungo, F.; Keller, G.; Lemercier, P.; Lieberherr, D.; Masson, P.; Moinat, M.; Pedruzzi, I.; Poux, S.; Rivoire, C.; Roechert, B.; Schneider, M.; Stutz, A.; Sundaram, S.; Tognolli, M.; Bougueleret, L.; Argoud-Puy, G.; Cusin, I. Duek- Roggli, P.; Xenarios, I.; Apweiler, R. The UniProt-GO Annotation database in 2011. Nucleic Acids Res.,  2012, 40(D1), D565-D570.
 [http://dx.doi.org/10.1093/nar/gkr1048] [PMID: 22123736]

[17]
Davis, A.P.; Wiegers, T.C.; Johnson, R.J.; Sciaky, D.; Wiegers, J.; Mattingly, C.J. Comparative Toxicogenomics Database (CTD): Update 2023. Nucleic Acids Res.,  2023, 51(D1), D1257-D1262.
 [http://dx.doi.org/10.1093/nar/gkac833] [PMID: 36169237]

[18]
Fishilevich, S.; Nudel, R.; Rappaport, N.; Hadar, R.; Plaschkes, I.; Iny Stein, T.; Rosen, N.; Kohn, A.; Twik, M.; Safran, M.; Lancet, D.; Cohen, D. GeneHancer: Genome-wide integration of enhancers and target genes in GeneCards. Database (Oxford),  2017, 2017, bax028.
 [http://dx.doi.org/10.1093/database/bax028] [PMID: 28605766]

[19]
Piñero, J.; Ramírez-Anguita, J.M.; Saüch-Pitarch, J.; Ronzano, F.; Centeno, E.; Sanz, F.; Furlong, L.I. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res.,  2019, 48(D1), gkz1021.
 [http://dx.doi.org/10.1093/nar/gkz1021] [PMID: 31680165]

[20]
Oliveros, J.C. Venny. An interactive tool for comparing lists with Venn's diagrams.  , 2007-2015. Avialable from:https://bioinfogp.cnb.csic.es/tools/venny/index.html

[21]
Doncheva, N.T.; Morris, J.H.; Holze, H.; Kirsch, R.; Nastou, K.C.; Cuesta-Astroz, Y.; Rattei, T.; Szklarczyk, D.; von Mering, C.; Jensen, L.J. Cytoscape stringApp 2.0: Analysis and visualization of heterogeneous biological networks. J. Proteome Res.,  2023, 22(2), 637-646.
 [http://dx.doi.org/10.1021/acs.jproteome.2c00651] [PMID: 36512705]

[22]
Gfeller, D.; Grosdidier, A.; Wirth, M.; Daina, A.; Michielin, O.; Zoete, V. SwissTargetPrediction: A web server for target prediction of bioactive small molecules. Nucleic Acids Res.,  2014, 42(W1), W32-W38.
 [http://dx.doi.org/10.1093/nar/gku293] [PMID: 24792161]

[23]
Szklarczyk, D.; Gable, A.L.; Nastou, K.C.; Lyon, D.; Kirsch, R.; Pyysalo, S.; Doncheva, N.T.; Legeay, M.; Fang, T.; Bork, P.; Jensen, L.J.; von Mering, C. The STRING database in 2021: Customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res.,  2021, 49(D1), D605-D612.
 [http://dx.doi.org/10.1093/nar/gkaa1074] [PMID: 33237311]

[24]
Dennis, G., Jr; Sherman, B.T.; Hosack, D.A.; Yang, J.; Gao, W.; Lane, H.C.; Lempicki, R.A. DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol.,  2003, 4(5), P3.
 [http://dx.doi.org/10.1186/gb-2003-4-5-p3] [PMID: 12734009]

[25]
Loeser, R.F.; Goldring, S.R.; Scanzello, C.R.; Goldring, M.B. Osteoarthritis: A disease of the joint as an organ. Arthritis Rheum.,  2012, 64(6), 1697-1707.
 [http://dx.doi.org/10.1002/art.34453] [PMID: 22392533]

[26]
Yang, M. Oral Gancao fuzi Decoction on combined with injection of sodium hyaluronate in the treatment of 60 patients with knee osteoarthritis. Chin. J. Traumatol.,  2012, 20, 9-11.

[27]
Xiang, X.; Zhou, Y.; Sun, H.; Tan, S.; Lu, Z.; Huang, L.; Wang, W. Ivabradine abrogates TNF-α-induced degradation of articular cartilage matrix. Int. Immunopharmacol.,  2019, 66, 347-353.
 [http://dx.doi.org/10.1016/j.intimp.2018.11.035] [PMID: 30521963]

[28]
Zhou, J.; Liu, S.; Qiu, B.; Hu, Q.; Ming, J.; Peng, H. Effects of hyaluronan on vascular endothelial growth factor and receptor-2 expression in a rabbit osteoarthritis model. J. Orthop. Sci.,  2009, 14(3), 313-319.
 [http://dx.doi.org/10.1007/s00776-009-1329-8] [PMID: 19499299]

[29]
Chen, X.; Hao, Y.; Wang, Z.; Zhou, J.; Jia, Q.; Qiu, B. The effect of vascular endothelial growth factor on aggrecan and type II collagen expression in rat articular chondrocytes. Rheumatol. Int.,  2012, 32(11), 3359-3364.
 [http://dx.doi.org/10.1007/s00296-011-2178-2] [PMID: 22045519]

[30]
Jansen, H.; Meffert, R.H.; Birkenfeld, F.; Petersen, W.; Pufe, T. Detection of vascular endothelial growth factor (VEGF) in moderate osteoarthritis in a rabbit model. Ann. Anat.,  2012, 194(5), 452-456.
 [http://dx.doi.org/10.1016/j.aanat.2012.01.006] [PMID: 22429866]

[31]
Jin, Q.; Zhu, Q.; Wang, K.; Chen, M.; Li, X. Allisartan isoproxil attenuates oxidative stress and inflammation through the SIRT1/Nrf2/NF κB signalling pathway in diabetic cardiomyopathy rats. Mol. Med. Rep.,  2021, 23(3), 215.
 [http://dx.doi.org/10.3892/mmr.2021.11854] [PMID: 33495841]

[32]
Song, W.; Zhang, Y.; Wang, J.; Ma, T.; Hao, L.; Wang, K. Antagonism of cysteinyl leukotriene receptor 1 (cysLTR1) by montelukast suppresses cell senescence of chondrocytes. Cytokine,  2018, 103, 83-89.
 [http://dx.doi.org/10.1016/j.cyto.2017.12.021] [PMID: 29331588]

[33]
Labuschagne, C.F.; Zani, F.; Vousden, K.H. Control of metabolism by p53 - Cancer and beyond. Biochim. Biophys. Acta Rev. Cancer,  2018, 1870(1), 32-42.
 [http://dx.doi.org/10.1016/j.bbcan.2018.06.001] [PMID: 29883595]

[34]
Lee, Y.J.; Kim, S.A.; Lee, S.H. Hyaluronan suppresses lidocaine-induced apoptosis of human chondrocytes in vitro by inhibiting the p53-dependent mitochondrial apoptotic pathway. Acta Pharmacol. Sin.,  2016, 37(5), 664-673.
 [http://dx.doi.org/10.1038/aps.2015.151] [PMID: 27041463]

[35]
Chen, W.P.; Xiong, Y.; Hu, P.F.; Bao, J.P.; Wu, L.D. Baicalein inhibits MMPs expression via a MAPK-dependent mechanism in chondrocytes. Cell. Physiol. Biochem.,  2015, 36(1), 325-333.
 [http://dx.doi.org/10.1159/000374075] [PMID: 25967971]

[36]
Wang, C.; Zeng, L.; Zhang, T.; Liu, J.; Wang, W. Tenuigenin prevents IL-1β-induced inflammation in human osteoarthritis chondrocytes by suppressing PI3K/AKT/NF-κB signaling pathway. Inflammation,  2016, 39(2), 807-812.
 [http://dx.doi.org/10.1007/s10753-016-0309-3] [PMID: 26846886]

[37]
Zhang, Q.; Lai, S.; Hou, X.; Cao, W.; Zhang, Y.; Zhang, Z. Protective effects of PI3K/Akt signal pathway induced cell autophagy in rat knee joint cartilage injury. Am. J. Transl. Res.,  2018, 10(3), 762-770.
 [PMID: 29636866]

[38]
Yang, Y.; Wang, Y.; Zhao, M.; Jia, H.; Li, B.; Xing, D. Tormentic acid inhibits IL-1β-induced chondrocyte apoptosis by activating the PI3K/Akt signaling pathway. Mol. Med. Rep.,  2018, 17(3), 4753-4758.
 [http://dx.doi.org/10.3892/mmr.2018.8425] [PMID: 29328385]

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1573409919666230605115940	Print ISSN 1573-4099
Publisher Name Bentham Science Publisher	Online ISSN 1875-6697

Current Computer-Aided Drug Design

Potential Mechanisms Underlying the Therapeutic Roles of Gancao fuzi Decoction in Cold-dampness Obstruction Syndrome-type Knee Osteoarthritis

Abstract Play Pause

Graphical Abstract

Related Journals

Related Books

Abstract